Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
about
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the futureEstimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AIndividualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?Different impact of factor VIII products on inhibitor development?Aspects of prophylactic treatment of hemophiliaProphylaxis in older Canadian adults with hemophilia A: lessons and more questionsHumanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatmentGeneric and disease-specific quality of life among youth and young men with Hemophilia in Canada.Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.Vascular remodeling underlies rebleeding in hemophilic arthropathyAdvances and challenges in hemophilic arthropathy.The burden of bleeding in haemophilia: is one bleed too many?Factor VIII therapy for hemophilia A: current and future issues.Prophylaxis in real life scenarios.Various regimens for prophylactic treatment of patients with haemophilia.The current status of prophylactic replacement therapy in children and adults with haemophilia.Assessments of outcome in haemophilia - what is the added value of QoL tools?Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage - the MUSFIH study.Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence.Haemophilia treatment in 2030.Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia.The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register.Future of haemophilia outcome assessment: registries are key to optimized treatment.2017 Clinical trials update: Innovations in hemophilia therapy.Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein.Low dose prophylaxis in Tunisian children with haemophilia.Efficacy and safety of point-of-care ultrasound-guided intra-articular corticosteroid joint injections in patients with haemophilic arthropathy.European retrospective study of real-life haemophilia treatment.Preventing bleeds by treatment: new era for haemophilia changing the paradigm.Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study.Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study.Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed.Improving haemophilia patient care through sharing best practice.Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry.
P2860
Q26853631-32306766-CFC4-4D6D-A0E4-AEBF16245964Q26865814-D08B1CB8-BEF9-4265-927C-FEB797C755DEQ28075081-1D4A18D2-DF32-42F4-8BFC-1ADC540E34D3Q28075208-BF288F47-B220-4143-A8AB-908A0EDEE411Q28075679-C827E679-8A47-4423-89FC-55F5CC4122D7Q28078562-0AB5D431-BB18-41F5-BF23-C2018F84201CQ35091077-6A63F646-C534-4872-925D-D52C47DA1F7AQ35613053-26BE36AD-E546-4B9F-BC7A-3052943D5ECCQ36011892-1AA8E9AB-0A4F-4A2B-AA62-40D2C6FF0BE6Q36189452-C676A574-F2C2-47FC-AA67-9F2D96F3D48BQ36199877-43BE2166-3A49-4BA7-B550-0F0E713D89A2Q37279529-F4ABF1A6-18BA-4FA0-8396-AC286947E822Q38182702-F8D3DA61-8241-4817-8093-A0D94A4518D1Q38203350-9760267A-5FA9-41C0-9D0D-B2DA203DBDD4Q38206859-11CC1619-D03B-4FE0-9ACC-2E3655595334Q38308200-97694B39-7823-4E38-BEA2-8D867A05C1A8Q38394904-0B2B3123-CEC9-423C-90CD-8401BD59851BQ38511447-E23EA3E5-3CD4-4AA3-867D-F38C729FD8E9Q38652396-B06E3084-7560-4155-8C2B-880AB8603621Q38749122-F79EF227-C08A-4A9F-AEFB-30F840F7F744Q38783210-DCFF3160-F479-48D4-A3FB-109706148FCFQ38842671-2EF4FFBF-D7E4-43C9-803B-25F376DD4318Q38843540-3FE087F6-774C-42FA-92C8-8F6998078333Q38844972-CF8C8973-D7F2-425F-B35D-150C78B986EBQ38864911-4AD07685-0CF8-4BF5-9082-C6823B2D408BQ38937725-523F0D2B-1139-49E0-B883-F8FACBFC8E1DQ38955500-0BDCBFD3-AE34-4663-AE7F-AD7E4993C807Q38996905-4193D7EE-7525-4947-94A7-30D16F1E29DAQ39030128-F118DA9D-664F-45EE-914F-9F8DCD328CF3Q39169130-643665D7-D57D-4926-8C35-D0E1997DEEBCQ39268322-3C544811-785B-4909-9B88-617E576FE7A4Q39609299-C044CA57-3ADA-4ECC-AD68-200FBBE6A198Q39835946-5AD17BD9-F25B-460B-B75D-BC99497ABC33Q39875977-F9E369A8-E81A-4B30-88EA-8E695D64AE1DQ40013630-4636305A-F60F-4027-9B4E-FECF65818FC9Q40045534-E35CC1EF-73EE-482D-8881-597B5F176E6DQ40176994-736111BB-F564-4F56-8300-CA4480BFDAFAQ40731272-97834BEC-65AA-426E-9B1E-3996A19A683CQ42643647-7B9CADAD-A703-4169-97C5-DF7F33F35735Q44739795-8F8049A6-550B-44A5-901C-70E1AFA63EEC
P2860
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intermediate-dose versus high- ...... come and costs since the 1970s
@en
Intermediate-dose versus high- ...... ome and costs since the 1970s.
@nl
type
label
Intermediate-dose versus high- ...... come and costs since the 1970s
@en
Intermediate-dose versus high- ...... ome and costs since the 1970s.
@nl
prefLabel
Intermediate-dose versus high- ...... come and costs since the 1970s
@en
Intermediate-dose versus high- ...... ome and costs since the 1970s.
@nl
P2093
P2860
P1433
P1476
Intermediate-dose versus high- ...... come and costs since the 1970s
@en
P2093
Erik Berntorp
H Marijke van den Berg
Margareta Holmström
Pia Petrini
Rolf Ljung
P2860
P304
P356
10.1182/BLOOD-2012-12-470898
P407
P577
2013-06-18T00:00:00Z